Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: Better response rate with earlier treatment

European Journal of Haematology

Volumn 79, Issue 4, 2007, Pages 305-309

  Maisnar, Vladimír ^a   Radocha, Jakub ^a   Büchler, Tomáš ^b   Bláha, Václav ^c   Malý, Jaroslav ^a   Hájek, Roman ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Monotherapy; Multiple myeloma; Relapse; Thalidomide; Treatment

Indexed keywords

MYRIN; THALIDOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CONTROLLED STUDY; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LIMB WEAKNESS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE MYELOMA; NAUSEA; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; REFRACTORY PERIOD; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; THALIDOMIDE; TIME FACTORS;

EID: 34548563833     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00930.x     Document Type: Article

References (27)

1. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006 108: 3458 64.
2. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999 341: 1565 71.
3. D'Amato RJ, Loughran MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994 91: 4082 5.
4. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivates augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001 98: 210 6.
5. Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivates. J Clin Oncol 2003 21: 4444 54.
6. Richardson PG, Hideshima T, Anderson K. Thalidomide: emerging role in cancer medicine. Annu Rev Med 2002 53: 629 57.
7. Barlogie B, Desikan R, Eddelmon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001 98: 492 4.
8. Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2005 132: 584 93.
9. Hus M, Dmoszynska A, Soroka-Wojtaszko M, et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001 86: 404 8.
10. Juliusson G, Celsing F, Turesson I, et al. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000 109: 89 96.
11. Palumbo A, Falco P, Ambrosini MT, et al. Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant. Eur J Haematol 2005 75: 391 5.
12. Tosi P, Zamagni E, Cellini C, et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 2002 87: 345 6.
13. Yakoub-Agha I, Attal M, Dumontet C, et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients. Report of the Intergroupe Francophone du Myelome (IFM). Hematol J 2002 3: 185 92.
14. Facon T. Advances in the treatment of elderly patients with multiple myeloma. Clin Adv Hematol Oncol 2006 4: 501 2.
15. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006 367: 825 31.
16. Grover JK, Uppal G, Raina V. The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma. Ann Oncol 2002 13: 1636 40.
17. Palumbo A, Rus C, Zeldis JB, et al. Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J Thromb Haemost 2006 4: 1842 5.
18. Durie BGM, Stepan DE. Low dose thalidomide alone and in combination: long term follow-up [Abstract 688]. Blood 2001 98 (Suppl. 1 163.
19. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell transplantation. Br J Haematol 1998 102: 1115 23.
20. Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006 20: 1467 73.
21. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981 47: 207 14.
22. Yakoub-Agha I, Doyen C, Hulin G, et al. A multicenter prospective randomised study testing non-inferiority of thalidomide 100 mg/day as compared with 400 mg/day in patients with refractory/relapsed multiple myeloma: results of the final analysis of the IFM 01-02 study [Abstract 7520]. Proc Am Soc Clin Oncol 2006 24: 427.
23. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006 24: 431 6.
24. Raza SN, Veksler Y, Sabir T, et al. Durable response to thalidomide in relapsed/refractory multiple myeloma [Abstract 726]. Blood 2000 96: 168a 9a.
25. Grosbois B, Bellissant E, Moreau P, et al. Thalidomide (Thal) in the treatment of advanced multiple myeloma (MM): a prospective study of 120 patients [Abstract 2213]. Blood 2001 98: 689a.
26. Schey SA, Cavenagh J, Johnson R, et al. An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk Res 2003 27: 909 14.
27. Alexanian R, Weber D. Thalidomide for resistant and relapsing myeloma. Semin Hematol 2000 37 (1 Suppl 3 22 5.